查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1535592

胰臟癌治疗市场 - 按癌症类型（外分泌、内分泌）、治疗类型（化疗、免疫疗法、荷尔蒙和标靶治疗）、给药途径（口服、肠胃外）、性别（男性、女性）、最终用途和预测（2024） - 2032)

Pancreatic Cancer Treatment Market - By Cancer Type (Exocrine, Endocrine), Treatment Type (Chemotherapy, Immunotherapy, Hormone & Targeted Therapy), Route of Administration (Oral, Parenteral), Gender (Male, Female), End-use & Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 185 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在重大研发进步的推动下，2024 年至 2032 年全球胰臟癌治疗市场的复合年增长率将达到 13.2%。由于其发现较晚且具有侵袭性，胰臟癌仍然是最具挑战性的癌症之一。然而，分子生物学、免疫疗法和个人化医疗的最新创新正在改变治疗模式。例如，2024 年 7 月，多伦多大学的研究人员发现了两个对促进胰臟肿瘤生长至关重要的基因。这些发现对于理解和治疗胰臟癌具有重要意义。

领先的製药公司和研究机构正在大力投资发现新的治疗方法，包括标靶治疗和联合治疗，为患者提供更有效和量身定制的解决方案。对与胰臟癌相关的基因突变和生物标记的日益了解也增强了早期检测和个人化治疗策略。随着这些进展的持续，对先进胰臟癌治疗的需求必将增加，推动市场成长并为更好的患者治疗结果带来希望。对这一领域研发的承诺突显了该行业致力于应对最艰鉅的癌症挑战之一的决心。

胰臟癌治疗产业的整体价值根据癌症类型、治疗类型、给药途径、性别、最终用途和地区进行分类。

根据癌症类型，内分泌胰臟癌领域的胰臟癌治疗市场收入从2024 年到2032 年将实现令人称讚的复合年增长率。的治疗方法。标靶治疗、免疫疗法和基因研究的进步正在推动市场发展，因为它们为更有效的治疗带来了新的希望。意识的提高和诊断技术的改进导致了早期检测，进一步刺激了对创新治疗方案的需求。随着研究不断揭示 PNET 的分子机制，市场有望成长，满足对先进治疗方案的迫切需求。

就治疗类型而言，从2024年到2032年，化疗领域将出现显着增长。新化疗药物和联合疗法的开发旨在提高患者的生存率和生活品质。越来越多的研究和临床试验着重于提高化疗的疗效和减少化疗的副作用。随着对胰臟癌生物学认识的加深，个人化化疗方案不断涌现，进一步推动了市场需求。化疗领域的持续创新对于满足更好的胰臟癌治疗的迫切需求至关重要。

2024年至2032年，欧洲胰臟癌治疗市场将呈现显着的复合年增长率。标靶治疗、免疫治疗和个人化医疗等创新方法的采用正在扩大。此外，欧洲研究机构和製药公司的合作正在加速临床试验和监管批准。这种对推动治疗方案的承诺极大地促进了欧洲胰臟癌治疗市场的发展，旨在提高患者的治疗效果和存活率。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 胰臟癌的发生率和盛行率不断增加
      • 治疗方式的进步
      • 人口老化加剧
    • 产业陷阱与挑战
      • 治疗费用高
      • 早期检测有限
  • 成长潜力分析
  • 监管环境
    • 我们
    • 欧洲
    • 亚太地区
  • 报销版图
  • 管道分析
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按癌症类型，2021 - 2032 年

  • 主要趋势
  • 外分泌胰臟癌
  • 内分泌胰臟癌

第 6 章：市场估计与预测：按治疗类型，2021 - 2032 年

  • 主要趋势
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 荷尔蒙治疗
  • 其他治疗类型

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

  • 主要趋势
  • 口服
  • 注射用

第 8 章：市场估计与预测：按性别划分，2021 - 2032 年

  • 主要趋势
  • 男性
  • 女性

第 9 章：市场估计与预测：依最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 肿瘤中心
  • 其他最终用户

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 11 章：公司简介

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Genentech (F. Hoffmann-La Roche Ltd.)
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • PharmaCyte Biotech, Inc.
  • Pfizer, Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
简介目录
Product Code: 9748

Global Pancreatic Cancer Treatment Market will witness 13.2% CAGR between 2024 and 2032, driven by significant research and development advancements. Pancreatic cancer remains one of the most challenging cancers to treat due to its late detection and aggressive nature. However, recent innovations in molecular biology, immunotherapy, and personalized medicine are transforming the treatment landscape. For instance, in July 2024, researchers at the University of Toronto identified two genes crucial in promoting tumor growth in the pancreas. These findings hold significant implications for understanding and treating pancreatic cancer.

Leading pharmaceutical companies and research institutions are investing heavily in discovering novel therapeutic approaches, including targeted therapies and combination treatments that offer more effective and tailored solutions for patients. The growing understanding of genetic mutations and biomarkers associated with pancreatic cancer is also enhancing early detection and personalized treatment strategies. As these advancements continue, the demand for advanced pancreatic cancer treatments is set to rise, driving market growth and offering hope for better patient outcomes. The commitment to R&D in this field underscores the industry's dedication to tackling one of the most formidable cancer challenges.

The overall Pancreatic Cancer Treatment Industry value is classified based on the cancer type, treatment type, route of administration, gender, end-use, and region.

Based on cancer type, the pancreatic cancer treatment market revenue from the endocrine pancreatic cancer segment will register a commendable CAGR from 2024 to 2032. Endocrine pancreatic cancer, or pancreatic neuroendocrine tumors (PNETs), presents unique challenges and requires specialized treatment approaches. Advances in targeted therapies, immunotherapies, and genetic research are driving the market as they offer new hope for more effective treatments. Increased awareness and improved diagnostic techniques are leading to earlier detection, further fueling demand for innovative treatment options. As research continues to uncover the molecular mechanisms of PNETs, the market is poised for growth, addressing the critical need for advanced therapeutic options.

In terms of treatment type, the chemotherapy segment will witness appreciable growth from 2024 to 2032. Chemotherapy remains a cornerstone in treating pancreatic cancer, especially in advanced stages where surgical options are limited. The development of new chemotherapeutic agents and combination therapies aims to improve survival rates and quality of life for patients. Increasing research and clinical trials focus on enhancing the efficacy and reducing the side effects of chemotherapy. As understanding of pancreatic cancer biology deepens, personalized chemotherapy regimens are emerging, further boosting market demand. The ongoing innovation in chemotherapy is crucial in addressing the urgent need for better pancreatic cancer treatments.

Europe pancreatic cancer treatment market will exhibit a notable CAGR from 2024 to 2032. European countries are investing heavily in research and development to discover novel treatments and improve existing ones. The adoption of innovative approaches such as targeted therapies, immunotherapy, and personalized medicine is expanding. Furthermore, collaborative efforts across European research institutions and pharmaceutical companies are accelerating clinical trials and regulatory approvals. This commitment to advancing treatment options is significantly boosting the pancreatic cancer treatment market in Europe, aiming to enhance patient outcomes and survival rates.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence and prevalence of pancreatic cancer
      • 3.2.1.2 Advancements in treatment modalities
      • 3.2.1.3 Rising ageing population
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Limited early detection
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Reimbursement landscape
  • 3.6 Pipeline analysis
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Exocrine pancreatic cancer
  • 5.3 Endocrine pancreatic cancer

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Chemotherapy
  • 6.3 Targeted therapy
  • 6.4 Immunotherapy
  • 6.5 Hormone therapy
  • 6.6 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Male
  • 8.3 Female

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals
  • 9.3 Oncology centers
  • 9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 AstraZeneca
  • 11.2 Bristol-Myers Squibb Company
  • 11.3 Celgene Corporation
  • 11.4 Eli Lilly and Company
  • 11.5 Genentech (F. Hoffmann-La Roche Ltd.)
  • 11.6 GlaxoSmithKline plc
  • 11.7 Merck & Co., Inc.
  • 11.8 Mylan N.V.
  • 11.9 Novartis AG
  • 11.10 PharmaCyte Biotech, Inc.
  • 11.11 Pfizer, Inc.
  • 11.12 Sanofi
  • 11.13 Sun Pharmaceutical Industries Ltd.
  • 11.14 Takeda Pharmaceutical Company Limited
  • 11.15 Teva Pharmaceutical Industries Ltd.